Historically, traditional whole cell, growth-based assays have been the single most productive approach to the identification of anti-infectives that inhibit bacterial proliferation. None the less, growth-based assays have a number of important limitations including relatively low sensitivity/dynamic range relative to molecular assays, inability to distinguish bacteriostatic from bactericidal molecules, and poor performance in clinically important phases of bacterial disease, such as biofilms. To address these limitations, a number of improved cell-based screening approaches have been developed, each successful in its own right, but each also with an inherent set of limitations. For instance, Alamar blue dye, which measures the respiratory activity of organisms, is arguably the gold-standard whole cell antimicrobial screening technique. But, the dye cannot be used to effectively screen respiratory defective bacterial populations, such as small colony variants. Nor does the dye allow for distinction between bacteriostatic and bactericidal agents. We have developed a novel assay of antibacterial activity that directly detects the killing of bacteria by measuring the release of th intracellular enzyme adenylate kinase (AK) into the culture medium as a reporter of cell death. Our recent publication validated the use of the assay in antimicrobial screening and established that it has three key features. First, the assay is applicable to screening virtually any bacterial population. Second, the assay performs with exquisite sensitivity. Third, the assay enriches for the identification of bactericidal agents. As such, we believe the AK assay provides a very powerful new screening option for antimicrobial drug discovery, particularly for pathogens or bacterial growth states that are of immense healthcare concern that cannot be readily screened using conventional growth- based approaches and for which bactericidal antibiotics are desired;three examples include non-replicating (and slow growing) Mycobacterium tuberculosis, bacteria within established biofilms, and bacterial small colony variants. Accordingly, this application is being submitted in response to PA-10-213, "Development of Assays for High Throughput Screening for use in Probe and Pre-therapeutic Discovery". Consistent with the goals of this program announcement, we propose to further develop and validate three AK-assay based high throughput screening strategies that would not be possible using growth based assays and for which bactericidal agents are needed. We will develop AK-based high throughput screens for agents that kill: 1) non-replicating (and slow growing) M. tuberculosis;2) bacteria within established biofilms;and 3) bacterial small colony variants.

Public Health Relevance

Current antibiotics have been developed to inhibit, or kill, actively replicating bacteria. At issue, many pathogens and bacterial disease states do not undergo rapid proliferation and thus are recalcitrant to antibiotic therapy even in the absence of antibiotic resistant determinants;three well-documented examples of immense healthcare concern include Mycobacterium tuberculosis, bacteria within established biofilms, and bacterial small colony variants. This project will develop novel high throughput screening approaches to identify antimicrobials that target these three bacterial populations.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI103507-01A1
Application #
8631305
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
Xu, Zuoyu
Project Start
2013-09-20
Project End
2016-08-31
Budget Start
2013-09-20
Budget End
2014-08-31
Support Year
1
Fiscal Year
2013
Total Cost
$375,986
Indirect Cost
$112,147
Name
University of Rochester
Department
Microbiology/Immun/Virology
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Blanchard, Catlyn; Brooks, Lauren; Ebsworth-Mojica, Katherine et al. (2016) Zinc Pyrithione Improves the Antibacterial Activity of Silver Sulfadiazine Ointment. mSphere 1:
Blanchard, Catlyn; Brooks, Lauren; Beckley, Andrew et al. (2016) Neomycin Sulfate Improves the Antimicrobial Activity of Mupirocin-Based Antibacterial Ointments. Antimicrob Agents Chemother 60:862-72
Dunman, Paul M; Tomaras, Andrew P (2015) Translational deficiencies in antibacterial discovery and new screening paradigms. Curr Opin Microbiol 27:108-13
Colquhoun, Jennifer M; Wozniak, Rachel A F; Dunman, Paul M (2015) Clinically Relevant Growth Conditions Alter Acinetobacter baumannii Antibiotic Susceptibility and Promote Identification of Novel Antibacterial Agents. PLoS One 10:e0143033
Forbes, Lauren; Ebsworth-Mojica, Katherine; DiDone, Louis et al. (2015) A High Throughput Screening Assay for Anti-Mycobacterial Small Molecules Based on Adenylate Kinase Release as a Reporter of Cell Lysis. PLoS One 10:e0129234
Eidem, Tess M; Lounsbury, Nicole; Emery, John F et al. (2015) Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrob Agents Chemother 59:2016-28
Blanchard, Catlyn; Barnett, Pamela; Perlmutter, Jessamyn et al. (2014) Identification of Acinetobacter baumannii serum-associated antibiotic efflux pump inhibitors. Antimicrob Agents Chemother 58:6360-70
Perlmutter, Jessamyn I; Forbes, Lauren T; Krysan, Damian J et al. (2014) Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus. J Med Chem 57:8540-62